Cue Biopharma financials
$25.51−7.07%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M | $3.2M | $3.5M | $1.1M |
| Gross profit | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M | $3.2M | $3.5M | $1.1M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$26.5M | -$41.6M | -$52.0M | -$53.2M | -$43.7M | -$45.0M | -$36.8M | -$38.7M |
| Net income | -$26.6M | -$40.7M | -$50.7M | -$53.0M | -$44.2M | -$44.8M | -$36.7M | -$39.0M |
| Net margin | −96.9% | −438.0% | −924.1% | −4257.8% | −295.6% | −1419.8% | −1061.2% | −3411.5% |
| Diluted EPS | $-8.40 | $-21.60 | $-33.30 | $-44.70 | $-42.30 | $-46.80 | $-49.80 | $-58.20 |
| EBITDA | -$25.6M | -$41.2M | -$51.4M | -$52.3M | -$42.5M | -$48.2M | -$36.0M | -$37.9M |
| Operating cash flow | -$21.7M | -$36.3M | -$40.0M | -$41.8M | -$38.8M | -$32.5M | -$30.8M | -$25.6M |
| Free cash flow | -$21.9M | -$36.4M | -$40.0M | -$42.0M | -$39.8M | -$33.1M | -$30.8M | -$27.5M |
| Diluted shares | 3.2M | 1.9M | 1.5M | 1.2M | 1.0M | 1.0M | 0.7M | 0.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.1M | $22.5M | $48.5M | $51.6M | $64.4M | $74.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $24.7M | $0.00 | $10.0M |
| Total debt | $689.0K | $4.3M | $8.2M | $10.0M | $0.00 | $0.00 |
| Total assets | $42.2M | $32.2M | $61.5M | $91.3M | $83.4M | $99.5M |
| Total liabilities | $15.8M | $14.7M | $24.4M | $25.6M | $17.9M | $20.6M |
| Shareholders' equity | $26.4M | $17.5M | $37.1M | $65.7M | $65.5M | $78.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology